| name | endo-colonoscopy-diagnosis |
| description | Suggests screening for colon neoplasia with colonoscopy at the time of acromegaly diagnosis to establish baseline colorectal cancer risk. Trigger when a patient receives a new diagnosis of acromegaly (elevated IGF‑1 with lack of GH suppression after oral glucose tolerance test). |
Screening colonoscopy at diagnosis
STEP 1 — Gather Information
Collect clinical features suggestive of acromegaly (acral enlargement, facial changes, diaphoresis, etc.), measure serum IGF‑1, and perform an oral glucose tolerance test with GH measurement to confirm lack of suppression (<1 µg/L).
Action: Confirm biochemical diagnosis of acromegaly (elevated IGF‑1 and lack of GH suppression after OGTT).
STEP 2 — Rule In / Rule Out
Is acromegaly biochemically confirmed?
- Yes: Proceed to colonoscopy screening.
- No: Do not perform colonoscopy for this indication; consider alternative diagnoses.
Action: If acromegaly is confirmed, proceed to colonoscopy; if not, do not perform screening colonoscopy for this indication.
STEP 3 — Classify or Stratify
All newly diagnosed acromegaly patients are candidates for baseline colonoscopy regardless of age or symptoms; no further stratification is required per guideline.
Action: Proceed to colonoscopy for all newly diagnosed acromegaly patients (no further stratification needed).
STEP 4 — Decide
Schedule a complete colonoscopy with adequate bowel preparation; perform the procedure, document any polyps or lesions, and remove or biopsy findings.
Action: Schedule and perform colonoscopy; document findings and recommend follow‑up per pathology.
Clinical Guardrails / Mimics / Pitfalls
- Do not delay colonoscopy while initiating medical therapy for acromegaly; baseline risk assessment should occur promptly.
- Do not rely on fecal immunochemical testing or sigmoidoscopy; colonoscopy is required to detect proximal lesions common in acromegaly.
- Avoid colonoscopy in patients with uncontrollable coagulopathy, recent myocardial infarction, or severe colitis unless cleared by gastroenterology.
- Remember that up to 19 % of patients <40 years may harbor neoplasia; age <50 does not exclude screening in this high‑risk group.
Concrete Clinical Example
A 42‑year‑old presents with enlarging hands and feet, jaw protrusion, and hyperhidrosis. Serum IGF‑1 is elevated at 320 ng/mL (age‑adjusted ULN 200 ng/mL). OGTT shows GH nadir of 2.1 µg/L (failure to suppress). Acromegaly is diagnosed. Colonoscopy performed at diagnosis reveals a 5 mm tubular adenoma in the sigmoid colon, which is removed via cold snare pathology. Follow‑up colonoscopy is scheduled in 5 years per adenoma guidelines.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
